Available Until 4/24/2024
View Cart

Clinical Decision-making in Prevention and Management of Clostridioides difficile Infection

Content Release Date: 2/8/2023
Expiration Date: 4/24/2024
Activity Type: Application-based
CE Credits: up to 2.50 contact hours (0.250 CEUs)
Activity Fee:  Free

Activity Overview

This series explores Clostridioides difficile guideline updates and their application, with a focus on the treatment and management of CDI, as well as the pharmacoeconomic and quality-of-life impacts of CDI.  

This course consists of three activities (see table below) and provides up to 2.50 hours of continuing pharmacy education credit.  

 

Clinical Decision-making in Prevention and Management of Clostridioides difficile Infection* 

This 1.5-hour interprofessional educational activity examines recent data on Clostridioides difficile infection (CDI) and uses a case-based approach to apply recent guideline recommendations to the treatment and management of CDI. CDI is the most common healthcare-associated infection and the most common cause of mortality in patients with gastroenteritis in the United States. CDI has been shown to be associated with increased morbidity, mortality, and healthcare costs, as well as negatively impacting the patient’s quality of life. Recent updates to guidelines have resulted in practitioners having varying treatment and management options for CDI. This series explores these guideline updates and their application, with a focus on those the treatment and management of CDI, as well as the pharmacoeconomic and quality-of-life impacts of CDI.

 

 

Ask the Experts: Existing and Novel Therapeutics in the Management of Recurrent Clostridioides difficile Infection**

This 1-hour interprofessional educational activity examines recent data on Clostridioides difficile infection (CDI) and uses a case-based approach to apply recommendations to the management of recurrent CDI (rCDI). CDI is one of the most common healthcare-associated infections and the most common cause of mortality in patients with gastroenteritis in the United States. rCDI has been shown to be associated with increased morbidity, mortality, and healthcare costs, as well as having a negative impact on the patient’s quality of life. Recent updates to guidelines have resulted in practitioners having varying treatment and management options for CDI. This webinar will review the pathogenesis of CDI that can lead to rCDI episodes and explore the role of current and emerging therapeutics in the interprofessional management of rCDI.

Engaging the Experts Podcasts

Keeping Pace with the Guidelines.  C diff Past, Present, and Future
CE Credits: 1.5 hours CE Credits: 1.00 hours CE Credits: none

*Please note, this activity was presented live on December 5, 2022 as part of the ASHP 2022 Midyear Clinical Meeting & Exhibition. You can only claim credit once for this activity; live or home study.

**Please note, this activity was presented as a live webinar on March 23, 2023. You can only claim credit once for this activity; live or home study.

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.





  The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This activity was planned to meet the educational needs of pharmacists and physicians who care for patients with Clostriodioides difficile infection. 

After participating in this CPE activity, learners should be able to:

Clinical Decision-making in Prevention and Management of Clostridioides difficile Infection
ACPE Number: 0204-0000-22-417-H01-P
Release Date: 2/8/23
Expiration Date: 4/24/24
Activity Type: Application-based

  • Identify the complex epidemiology and pathogenesis of recurrent Clostridioides difficile (CDI). 
  • Analyze recently released therapeutic guidelines and recommendations for the treatment of primary and recurrent CDI in adults. 
  • Develop an interprofessional treatment plan for recurrent CDI. 
  • Evaluate the quality-of-life impacts of CDI on patient. 

The American Society of Health-System Pharmacists designates this internet enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Ask the Experts: Existing and Novel Therapeutics in the Management of Recurrent Clostridioides difficile Infection
ACPE Number: 0204-0000-23-404-H01-P
Release Date: 4/24/23
Expiration Date: 4/24/24
Activity Type: Application-based

  • Analyze the pathogenesis of recurrent Clostridioides difficile infection (rCDI).
  • Evaluate current and emerging therapies for the prevention of rCDI.
  • Recommend evidence-based strategies for the use of emerging therapies in the interprofessional management of rCDI.

The American Society of Health-System Pharmacists designates this internet enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Anne Gonzales-Luna, PharmD, BCIDP
Research Assistant Professor - Infectious Diseases 
University of Houston College of Pharmacy  

Anne J. Gonzales-Luna, Pharm.D., BCIDP, is Assistant Professor at the University of Houston College of Pharmacy in Houston, Texas. 

Dr. Gonzales-Luna earned her Doctor of Pharmacy degree from the University of Texas College of Pharmacy in Austin, and completed an ASHP-accredited postgraduate year 1 (PGY1) residency at the Michael E. DeBakey Veterans Affairs Medical Center in Houston. Following her residency, Dr. Gonzales-Luna completed an Infectious Diseases Pharmacotherapy fellowship at the University of Houston College of Pharmacy, with a research focus on Clostridioides difficile. 

Dr. Gonzales-Luna serves as a preceptor for Antimicrobial Stewardship and Research rotations for fourth-year pharmacy students, as well as the Infectious Diseases Pharmacotherapy Fellowship program coordinator. 

Dr. Gonzales-Luna is a member of ASHP, the Society of Infectious Diseases Pharmacists (SIDP), American College of Clinical Pharmacy (ACCP), the Texas Society of Health-System Pharmacists (TSHP), and the Gulf Coast Society of Health System Pharmacists (GCSHP). 

.


Andrew Skinner, MD
Assistant Professor of Medicine
Loyola University Medical Center   

Dr. Andrew Skinner is a Clinical Instructor at Loyola University Medical Center within the Division of Infectious Diseases. Dr. Skinner completed his internal medicine residency at University of Chicago (NorthShore) and his infectious diseases fellowship at Loyola University Medical Center. Dr. Skinner’s research interests are the molecular and clinical epidemiology and pathogenesis of Clostridioides difficile. His clinical interests are dedicated to the treatment of individuals with multiple recurrent C. difficile infections. Dr. Skinner is a member of the Infectious Diseases Society of America (ISDA) and is a member of the C. difficile Focused Treatment Update guideline committee. 

The following persons in control of this activity’s content have relevant financial relationships:

  • Kevin Garey– Paratek Pharmaceuticals: PI on grants; Acurx Pharmaceuticals: PI on grants; Summit Pharmaceuticals: PI on grants

All other persons in control of content do not have any relevant financial relationships with an ineligible company.

As defined by the Standards of Integrity and Independence in Accredited Education definition of ineligible company. All relevant financial relationships have been mitigated prior to the CE activity.

Activities can be completed in any order. Each activity consists of audio and video and an evaluation. Learners must review all content and complete an evaluation to receive continuing education credit for each activity.

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.

Per ACPE requirements, CPE credit must be claimed within 60 days of being earned – no exceptions! To verify that you have completed the required steps and to ensure your credits have been reported to CPE Monitor, we encourage you to check your NABP eProfile account to validate your credits were transferred successfully before the ACPE 60-day deadline. After the 60 day deadline, ASHP will no longer be able to award credit for this activity.

 

Provided by ASHP

Supported by an educational grant from Merck